Search results for: “Biosimilar”

In the ongoing effort to balance medical innovation with patient access, federal regulators have officially unveiled a comprehensive strategy to stimulate the marketplace for follow-on biological products.

The Food and Drug Administration introduced its Biosimilars Action Plan as a crucial component of its broader initiative to tackle escalating prescription costs and drug monopolies. This strategic roadmap aims to aggressively promote competition, reduce regulatory friction, and improve the overall affordability of life-saving biological medications across the United States.

Structuring the Competitive Landscape

The agency’s leadership designed the new regulatory blueprint to address the inherent tension between protecting new therapeutic discoveries and expediting the approval of more affordable alternatives. The overarching goal is to maintain a continuous cycle of innovation while actively removing the bureaucratic bottlenecks that historically stifle market entry. To achieve this delicate balance, the plan focuses heavily on four fundamental pillars of targeted regulatory reform and proactive market support.

First, the agency intends to drastically improve the overall efficiency of the product development and statutory application review processes. Second, federal regulators are prioritizing targeted initiatives that maximize scientific and regulatory clarity for manufacturers navigating these complex approval pathways. The remaining pillars focus on developing effective educational communications for healthcare providers and actively thwarting corporate behaviors that intentionally delay market access.

Prioritizing Key Regulatory Deliverables

To execute these broad objectives, the strategic roadmap identifies a series of specific, actionable priority deliverables intended to streamline industry compliance. One major initiative involves transforming the existing Purple Book into a highly enhanced, user-friendly online database containing comprehensive product exclusivity information. The agency will also create advanced analytical tools and reference indexes to assist commercial sponsors in developing high-quality interchangeable products using state-of-the-art techniques.

Furthermore, federal health regulators are actively exploring global harmonization efforts to properly support a robust international market for follow-on biologics. This massive undertaking includes establishing secure data-sharing agreements with peer regulatory authorities in Europe, Japan, and Canada to better align global approval standards. To further reduce development costs, the agency is even considering policies that would allow domestic developers to utilize non-domestic comparator products to support their domestic licensing applications.

Combating Market Manipulation

Beyond simply streamlining internal review processes, the new regulatory plan takes a remarkably firm stance against aggressive corporate tactics designed to artificially extend lucrative market monopolies. The agency has formally pledged to collaborate directly with the Federal Trade Commission to identify, investigate, and neutralize anti-competitive behavior within the broader pharmaceutical industry. Regulators also plan to work closely with federal lawmakers to systematically close existing legislative loopholes that actively encourage the gaming of strict statutory requirements.

Agency leadership has also openly acknowledged that the remarkably high cost of biological therapies is heavily influenced by systemic commercial reimbursement pressures operating outside of their direct jurisdiction. Top officials have publicly suggested that transitioning the industry toward competitively bid reimbursement schemes would help the healthcare system fully leverage multi-source market competition. Ultimately, this aggressively proactive regulatory posture signals a definitive, long-term shift toward prioritizing consumer affordability in the highly complex and profitable biological drug sector.

The legal landscape for biological products experienced a significant shift following a highly anticipated Supreme Court opinion. Industry stakeholders closely watched this landmark case because it represented the highest court’s first direct engagement with biosimilar regulations. The unanimous decision ultimately reversed a previously split opinion from the Federal Circuit Court of Appeals.

This judicial intervention specifically addressed the complex statutory framework of the Biologics Price Competition and Innovation Act. A central conflict in the litigation revolved around the proper interpretation of a mandatory 180-day notice provision. The lower appellate court had previously established a rigid timeline that heavily favored original drug manufacturers.

Understanding the Notification Timeline

Under the overturned Federal Circuit interpretation, biosimilar applicants faced a strict and delayed notification requirement. The lower court mandated that competing manufacturers could only provide their commercial marketing notice after securing final agency licensure. This interpretation essentially granted reference product sponsors an automatic, unintended six-month extension of lucrative market exclusivity.

Justice Thomas authored the unanimous opinion that completely dismantled this delayed notification requirement. He emphasized a plain reading of the legislative text, noting that the statute only contained a single timing condition. If federal lawmakers had intended to impose a dual-timeline requirement, they would have explicitly drafted the legislation to reflect that constraint.

Practical Implications for Manufacturers

This ruling represents a massive legal victory for biosimilar developers seeking faster market entry. Companies can now technically submit their commercial marketing notices much earlier in the federal regulatory review process. However, this newfound flexibility introduces interesting public policy questions regarding the most appropriate timing for such critical notifications.

Providing notice concurrently with an initial application submission might not offer much practical benefit to either party. The regulatory review process is inherently unpredictable, and the agency frequently identifies deficiencies that delay final licensure. It remains entirely uncertain whether developers will actually adopt this aggressive early-notification strategy despite having the legal clearance to do so.

Ongoing Regulatory Advancements

While the legal community dissected the Supreme Court ruling, federal health regulators continued advancing new biological products. The agency recently granted approval for a second biosimilar alternative to the popular reference product Remicade. This regulatory approval signals a steadily maturing administrative pathway for these complex, cost-saving therapeutic alternatives.

Furthermore, specialized advisory committees are actively evaluating several other high-profile pharmaceutical applications. An oncology advisory panel recently voted favorably to recommend the very first biosimilar version of Epogen for full approval. This same specialized committee is already scheduled to review applications targeting other blockbuster biologic treatments like Herceptin and Avastin.

Looking Toward State Legislation

Federal court rulings and agency approvals only represent a portion of the broader regulatory picture. State legislative sessions across the country have recently concluded, bringing potential changes to local pharmacy dispensing rules. Industry observers are now actively analyzing these updated state laws to understand new substitution requirements for interchangeable biological products.

These intersecting legal and regulatory developments are rapidly shaping the future of competitive healthcare pricing nationwide. As more affordable alternatives clear these legal hurdles, patient access to essential biological therapies will likely expand. The coming months will prove critical as pharmaceutical manufacturers adjust their market strategies to align with these new judicial precedents.

In March, the Food and Drug Administration published a highly anticipated draft guidance document. This important regulatory publication outlines specific recommendations for the labeling of newly developed prescription biosimilar products. Medical professionals and pharmaceutical manufacturing companies have eagerly waited many long years for these specific biological product approval pathway rules.

Understanding Biological Product Complexity

The underlying concept is that biological products are complex molecules created within living organisms. Creating an exact duplicate of these original reference products is scientifically impossible due to their structural complexities. Regulators created an approval pathway for medicines that are highly similar to the original biologic.

Under the newly published guidelines, the federal agency clearly distinguishes between standard generic drugs and these advanced biosimilars. Generic drugs are exact chemical copies that typically share the exact same labeling as their brand name counterparts. Biosimilars require a much more nuanced approach to prescription labeling to ensure patient safety.

The core philosophy of this draft document is that biosimilar labels should rely heavily upon the established reference product label. Manufacturers do not need to create entirely new prescribing information from scratch when introducing their alternative treatments. They can leverage the comprehensive safety profile already established by the originator brand.

However, the agency explicitly recommends against including specific clinical data derived directly from the biosimilarity studies. The government argues that these specific comparative studies are uniquely designed only to prove similarity rather than independent safety. Including this highly technical comparative data could easily confuse prescribing physicians and other healthcare practitioners.

Navigating Strict Naming Conventions

Instead of displaying their own clinical trial results, biosimilar labels must display the clinical data of the reference product. This approach ensures that medical professionals base their treatment decisions on the robust historical evidence available. Any modifications to this shared information must be considered and justified.

The draft text also introduces strict naming conventions to prevent medication errors in pharmacies and hospitals. When a label section discusses information specific to the alternative medicine, the document must use the proprietary biosimilar product name. This specific naming rule applies heavily to administration instructions and dosage form label descriptions.

Conversely, the label must use the reference product name when describing historical clinical trials and adverse reaction statistics. Using the original brand name in these sections accurately attributes the source of the foundational clinical data. It prevents any misleading implication that the alternative manufacturer conducted those massive original efficacy trials.

A third naming category involves the use of a shared core name when discussing general risks associated with the substance. If an adverse event applies equally to both the reference drug and the biosimilar, the label utilizes the core chemical name followed by the word products. This promotes broad clarity.

One of the most notable requirements is the mandatory inclusion of a specific biosimilarity statement near the top. This clear disclaimer must appear directly below the initial United States approval date within the highlights section. It explicitly informs the prescribing physician that the product was approved via this abbreviated pathway.

This required statement must be accompanied by a detailed footnote explaining the legal definition of biological similarity. The footnote clarifies that approval requires data demonstrating no clinically meaningful differences between the two related biological products. Industry stakeholders requested this explicit disclaimer to prevent any confusion regarding these underlying testing methodologies.

Addressing Inherent Immunogenicity Risks

Immunogenicity remains a concern when dealing with any protein based treatments injected into the body. The immune system can unpredictably react to even the smallest structural variation between the reference product and its copy. Therefore, regulators provided instructions on how to describe these immunological risks accurately.

Labels must clearly indicate that immunogenicity data is highly dependent on the specific sensitivity of the test used. Comparing reaction rates across different products using different testing assays can be incredibly misleading for prescribing doctors. The guidance ensures that clinicians understand these statistical limitations before making critical patient treatment decisions.

Another critical distinction involves the ongoing responsibility of the manufacturer to maintain accurate and updated safety warnings. Generic drug makers traditionally enjoy a passive role where they merely mirror the safety updates published by brand owners. Biosimilar sponsors do not share this exact same passive legal shield under current regulations.

These specialized sponsors must actively monitor various adverse event databases to identify any newly emerging clinical risks. If a new safety concern appears during widespread commercial use, the sponsor must independently update their product labeling. This continuous monitoring requirement could expose alternative manufacturers to increased product liability litigation over time.

Legal experts predict that this distinction will play a major role in future state level failure to warn lawsuits. Patients harmed by unforeseen side effects might argue that the alternative manufacturer failed to independently warn them appropriately. The evolving legal landscape makes compliance with this specific guidance document absolutely essential.

The guidance intentionally excludes recommendations for biological products seeking the highly coveted interchangeable regulatory status from the federal government. Interchangeable products face an even higher evidentiary burden to prove they produce identical clinical results without additional risks. Regulators promised to issue separate rules regarding that specific substitution tier later on.

Establishing Strict Legal Boundaries

By separating standard similarity from complete interchangeability, the government established a tiered system for biological medicines today. Pharmacists cannot automatically substitute a standard biosimilar for the brand name without explicit physician authorization first. The labeling rules reflect this boundary by keeping the original brand prominent throughout.

The federal agency accepted public feedback regarding this comprehensive regulatory proposal for exactly sixty days after its initial publication. Pharmaceutical executives and patient advocacy groups quickly submitted extensive commentary addressing the complexities of these new administrative rules. Balancing corporate commercial interests with pristine patient safety remained the ultimate regulatory challenge.

Several major drug manufacturers expressed initial concerns about their ability to market their alternative products effectively under these guidelines. They worried that forcing their labels to look nearly identical to the reference product would hinder market differentiation efforts. However, preventing dangerous medical mistakes at the pharmacy counter superseded marketing concerns.

Other stakeholders praised the federal regulators for prioritizing transparency and establishing firm boundaries regarding the display of trial data. Allowing companies to publish their own similarity studies could have flooded the market with contradictory and confusing statistical noise. A unified labeling approach guarantees that all prescribers read consistent scientific information.

The ultimate success of this abbreviated regulatory pathway depends entirely upon building immense trust within the broader medical community. Doctors will simply refuse to prescribe these cheaper alternatives if they doubt the accuracy of the printed prescription labels. Clear guidelines foster confidence and accelerate widespread clinical adoption across the country.

Financial analysts predicted that lowering barriers for biological copies would save the healthcare system billions of dollars annually worldwide. Monopolies on complex intravenous treatments have historically driven medical insurance premiums upward at completely unsustainable macroeconomic inflation rates. Introducing generic competition into this specialized sector rapidly lowers those massive patient costs.

Fostering Widespread Clinical Adoption

Before these regulations existed, companies struggled to navigate the ambiguous administrative process associated with launching alternative treatments. Legal uncertainty surrounding the approval process often discouraged smaller biotech companies from investing in manufacturing biological copies. The publication of this draft provided needed administrative predictability for corporate investors.

As the medical industry continues expanding, these foundational naming and reporting conventions will shape countless future pharmacological developments globally. Providing healthcare professionals with transparent and easily digestible information ultimately guarantees much better clinical outcomes overall. Safe biological competition truly represents the absolute pinnacle of modern pharmaceutical health law policy development.

The successful integration of these advanced biological medicines relies heavily upon continued collaborative dialogues between regulators and industry leaders. Establishing rigid labeling frameworks ensures that patients always receive the most accurate scientific information regarding their prescriptions. Every new policy refinement strengthens the underlying integrity of the entire national healthcare apparatus.

Looking forward, federal authorities will inevitably refine these preliminary draft guidelines as technological capabilities within biological manufacturing systematically evolve. However, the core philosophies emphasizing extreme caution and absolute transparency will undoubtedly remain permanently intact. This regulatory milestone ultimately protects vulnerable patients while simultaneously fostering massive economic growth across the sector.

After considerable pressure from industry stakeholders and healthcare practitioners, federal regulators have officially proposed a new naming convention for biological products. The Food and Drug Administration recently published a draft guidance outlining how it intends to assign nonproprietary names to both original biologics and abbreviated biosimilars. This highly anticipated policy shift aims to create a standardized framework that fundamentally alters how these complex medications are identified.

Under the proposed guidelines, every biological product would receive a proper name consisting of two distinct structural components. The first portion involves a shared core name based on the reference product’s active drug substance. The second portion requires the addition of a unique, four-letter lowercase suffix attached by a hyphen.

Regulators stipulate that this mandatory suffix must be completely devoid of any specific meaning or recognizable abbreviations. It cannot imply anything about the safety or effectiveness of the medication, nor can it serve as a promotional tool for the manufacturer. This strict naming structure is designed to apply retrospectively to already approved biologics as well as all future market approvals.

Enhancing Patient Safety and Pharmacovigilance

The primary catalyst behind this unique naming convention is the urgent need to prevent inadvertent medication substitution. Biologics and biosimilars are highly complex molecules, meaning a biosimilar is not automatically deemed interchangeable with its reference product. By assigning unique suffixes, the agency hopes to stop dispensing errors that could lead to unintended alternating of distinct treatments.

Furthermore, the distinct four-letter codes will significantly bolster national pharmacovigilance efforts and post-market surveillance. When adverse events inevitably occur, healthcare providers can use the specific suffix to precisely track which manufacturer’s product a patient received. This granular level of tracking is absolutely essential for monitoring safety profiles across various outpatient clinics and hospital systems.

The Debate Over Interchangeable Products

While the draft guidance establishes clear rules for standard biosimilars, it intentionally leaves the door open regarding interchangeable products. The agency is actively seeking public commentary on whether an interchangeable biologic should simply share the exact same suffix as its reference product. Alternatively, regulators are considering whether they should require a distinctly unique suffix even if the product meets the rigorous standards for interchangeability.

This unresolved question represents a massive policy hurdle that could heavily influence market competition and routine pharmacy dispensing practices. Pharmaceutical companies and pharmacy benefit managers are closely evaluating how either regulatory outcome would impact their electronic databases and inventory management systems. Ultimately, the broader healthcare industry must actively engage during the comment period to help shape the final regulatory landscape.

It appears that – at least for now – the U.S. Food and Drug Administration (FDA) is serving as the public face of the executive branch’s efforts to tackle the increasingly contentious debate about prescription drug prices. As we previously reported, following a May 25, 2017 budget hearing, FDA Commissioner Scott Gottlieb has made increased competition in the drug marketplace a high policy priority for the Agency. To that end, we have recently seen concrete steps being taken to advance Dr. Gottlieb’s multi-pronged “Drug Competition Action Plan.”

First, on June 27, 2017, the Agency issued a revised procedure for the Office of Generic Drugs, the “Prioritization of Review of Original ANDAs, Amendments, and Supplements” (MAPP 5240.3). The internal procedure now allows the first 3 generic drug applications for a particular reference product (known as Abbreviated New Drug Applications or ANDAs) to receive priority review. The existing policy had been that such expedited, priority review was available only to the first ANDA to be submitted for a reference drug product. As the Agency noted in a same-day announcement, it “revised this policy based on data that indicates consumers see significant price reduction when there are at least three FDA-approved generics available.” Under the GDUFA II agreement negotiated with industry, priority-assigned ANDAs would receive an 8-month review deadline, while standard applications would receive a 10-month review deadline.

Second, in order to support its 8-month ANDA priority review commitment, the Agency released a draft guidance related to Pre-Submission Facility Correspondence. The draft guidance explains that detailed information about the manufacturing facility (or facilities) for a proposed generic drug product should be filed 2 months before the ANDA is expected to be submitted. That pre-submission information would permit FDA to make initial assessments about the facilities, such as determining whether they need to be inspected and scheduling foreign inspections in a more timely manner, which would then speed up the review of the ANDA itself and make it more likely that priority user fee goals can be met.

Third, also on June 27th, FDA published its first iteration of a “List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic,” aimed at increasing transparency and potentially spurring new generic drug development. The list is expected to be updated every 6 months, and although it was compiled based on already-public information from FDA’s Orange Book, the existence of a single list surely could be more convenient for many companies. In addition, the list is split into two sections: drug products “for which FDA could immediately accept an ANDA without prior discussion” and “drug products involving potential legal, regulatory, or scientific issues which should be addressed with the Agency prior to submission of an ANDA.” The distinction between these two buckets of drugs without generic competition will be important for smaller companies who may review the list with an eye to developing new generic products. But it’s unclear whether this new compilation will necessarily spur brand new investments in the generic drug industry.

Last, although certainly not least, the Agency is convening a public meeting on July 18, 2017 to solicit input on “how best to preserve the balance Congress intended to strike in the Hatch-Waxman Amendments between encouraging innovation in drug development and accelerating the availability to the public of lower cost alternatives to innovator drugs.” The public meeting was announced by Dr. Gottlieb in a FDA Voice Blog post outlining the Drug Competition Action Plan, and the meeting webpage (available here) provides a link to the formal notice that lists several questions related to generic drug development on which the Agency seeks feedback. The event is likely to attract high-level policymakers from diverse sectors of the pharmaceutical economy, and hopefully FDA will make time to hear from all those diverse viewpoints.

Readers who have been following Dr. Gottlieb’s position on drug competition and FDA’s role in the supply chain may also be aware that he’s articulated a goal of clearing out the entire backlog of generic drug applications. And there are additional actions that the Agency expects to roll out as part of the Drug Competition Action Plan, separate and apart from any initiatives they may develop following the July 18th public meeting and its review of stakeholder comments submitted in response to the meeting notice (which will be due by September 18, 2017). However, at the same time, FDA is facing crunch time for Congress to pass the FDA Reauthorization Act (FDARA) in order to re-up the Agency’s four major user fee programs (prescription drugs, generic drugs, biosimilars, and medical devices).

With a critical end-of-July deadline looming, and House and Senate committee-passed versions of FDARA still needing to be reconciled and voted on in both chambers, there is a lot of work left to be done. There are very few work days left before Congress breaks for a month-long August recess (13 days for the House and 15 days for the Senate). So it remains to be seen whether any of these recent changes under the Drug Competition Action Plan could be shelved if GDUFA II is not passed and FDA does not continue to have authorization to collect user fees from generic drug applicants.

During his first appearance before Congress as FDA Commissioner on May 25, 2017, Scott Gottlieb reported that the Agency is preparing a “Drug Competition Action Plan” that it will unveil in upcoming weeks and months. This was likely welcome news to many politicians from both parties, as well as to President Trump, who has publicly shamed pharmaceutical companies for the high prices of their products but has done little to advance concrete policies in this area.

Dr. Gottlieb has been consistent over the years, including during his recent confirmation process, in his view that FDA should take a more active role in fostering competition and reducing unnecessary regulatory barriers. So it was not surprising when he was selected by Trump to lead the Agency, nor when he received a relatively warm welcome from Senators concerned about the direction prices have been going in recent years. Although it’s not expected to be a magic bullet that will automatically result in price reductions or cost savings for insurers and patients, a more competitive marketplace for drugs and biologics may have an impact on some of the factors that contribute to what many stakeholders feel are unreasonably high drug prices.

Some of the elements Dr. Gottlieb suggested may be included in the upcoming FDA Drug Competition Action Plan include:

1. Publish (and regularly update) a list of drugs that are off-patent but are not subject to any generic competition;
2. Issue more useful guidance for small-molecule generic companies to increase the likelihood an application will be approved first-cycle (a well-known problem in this industry is that applications are often poor-quality and may need several FDA review cycles before achieving success;
3. Modernize/standardize the regulatory process for complex drugs (like EpiPen) to make follow-on generic products easier to develop;
4. Clear out the entire backlog of generic drug applications; and
5. Implement certain Risk Evaluation and Mitigation Strategies (REMS) reforms that can be done without a need for statutory changes, such as waiving the requirement that a brand and a generic develop a “shared REMS.”

Dr. Gottlieb also noted that one of the goals of this broader initiative is to “curtail gaming by industry of our regulations which can extend monopolies beyond the timeframe that Congress intended, hindering competition.”

On that point, REMS that incorporate restricted-distribution programs for the products they cover have been cited for years as impeding the rapid development of generic and biosimilar versions of those products. Dr. Gottlieb indicated that he and his staff would also be convening a Part 15 public hearing to gather input from stakeholders about how and when alleged manipulation of the REMS system occurs, and the best ways for FDA to address such issues. At least two bills have been introduced in the current Congress to make changes to the legal provisions that created the Agency’s REMS authorities in 2007, and many others have failed in prior years. We will be watching how FDA tackles this and other controversial policy changes.  Stay tuned!

The Senate Health, Education, Labor and Pension Committee voted overwhelmingly to support the FDA Reauthorization Act. This critical bipartisan legislative effort, formally navigating Congress as FDARA, advanced with near-unanimous approval from the panel. The pivotal committee vote coincided closely with the swift congressional confirmation and swearing-in of the new agency commissioner, Dr. Scott Gottlieb.

With new leadership suddenly at the helm, the regulatory agency faced immediate political pressure from various industry stakeholders. Healthcare advocates urged federal lawmakers to enact the pending user fee legislation promptly to avoid any disruption of essential administrative operations. This legislation remains absolutely critical because it officially reauthorizes the federal authority to collect necessary user fees from medical product developers.

These mandatory financial fees apply broadly to manufacturers of pharmaceuticals, medical devices, generic drugs, and biosimilar products. At the time of the legislative committee vote, the existing statutory authority for these vital funding programs was rapidly approaching its scheduled expiration date. The approved bill subsequently moved to the broader Senate floor, while the House of Representatives counterpart awaited further committee markup scheduling.

Exploring the New Policy Riders

Just days before the final committee vote, lawmakers introduced a comprehensive manager’s amendment that attached several substantive policy changes. Legislators deliberately excluded highly controversial proposals, such as those attempting to address lab-developed tests and off-label pharmaceutical promotion. Instead, the committee focused on targeted regulatory adjustments intended to streamline specific medical approval pathways and improve public health outcomes.

One prominent amendment explicitly requires health regulators to develop specific bioequivalence guidance tailored to complex generic drugs. The legislative package also incorporates modern medical device policies that facilitate risk-based facility inspections and address over-the-counter consumer hearing aid sales. Furthermore, it includes targeted measures specifically designed to encourage earlier planning for necessary pediatric clinical studies in drug development.

Another highly significant rider makes important technical adjustments to the established federal Orphan Drug Act. This specific statutory provision formally codifies the federal regulatory interpretation of the complex “clinical superiority” requirement. This administrative interpretation had faced repeated, aggressive legal challenges from pharmaceutical applicants in federal courts over the preceding years.

Addressing Controversial Legislative Additions

During the actual markup hearing, committee members successfully added two more provisions through a standard voice vote. The first requirement forces the federal agency to host a public meeting to explore increasing patient access to experimental medications. Industry analysts suggest this specific inclusion was a strategic maneuver to stall a more contentious federal “Right-to-Try” mandate from gaining momentum.

A second late legislative addition formally directs health regulators to expedite their review processes for specific generic drug applications. Conversely, the committee swiftly tabled a highly debated amendment that would have permitted the widespread importation of Canadian prescription drugs. Committee leadership emphasized the desperate need to keep the legislative package completely bipartisan to ensure a smooth, timely passage through Congress.

Evaluating Programmatic Fee Restructuring

Beyond the newly attached policy riders, the core user fee agreements introduce substantial structural changes to the underlying financing programs. For instance, regulators are completely phasing out established user fees for supplemental drug and biologic applications. Simultaneously, the federal agency is actively implementing brand new administrative charges, including targeted fees for de novo medical device applications.

This broad fee consolidation strategy means that some individual medical manufacturing companies may ultimately face higher total financial obligations. Industry stakeholders must carefully analyze these massive programmatic shifts to determine the precise long-term impact on their operational budgets. Thoroughly understanding these evolving financial requirements is essential for maintaining strict compliance and securing future medical product development partnerships.

As we noted previously in our introductory blog post on the 2017 User Fee Act (UFA) reauthorization process, the first UFA hearing on Capitol Hill was convened on March 2, 2017 by the House Energy & Commerce Committee’s (E&C) Subcommittee on Health.  That hearing focused on the UFAs specific to generic drugs and biosimilar biological products.  Since then, Congress has held several more UFA hearings, and multiple FDA-related bipartisan bills that could become important to this process have been introduced.  So it’s time for an update on how things are going with the UFA reauthorizations.

First, the following relevant hearings have taken place in the intervening weeks:

• March 21, 2017 – Senate Health, Education, Labor and Pensions (HELP) Committee hearing on all four user fee programs (PDUFA, MDUFA, GDUFA, and BsUFA – look back at our previous intro post if you don’t know these acronyms!). The witnesses at this first HELP hearing on user fees were the three directors of FDA’s Centers for Devices, Drugs, and Biologics.
• March 22, 2017 – House Oversight and Government Reform Committee, Subcommittee on Health Care, Benefits, and Administrative Rules, hearing on restrictive drug distribution programs and their impact on generic drug development.
• March 22, 2017 – House E&C Subcommittee on Health hearing to examine PDUFA.
• March 28, 2017 – House E&C Subcommittee on Health hearing to examine MDUFA.

In addition, the HELP Committee is planning another user fee-focused hearing, likely to take place on April 4, to hear perspectives from patients, drug manufacturers, and others on the reauthorization agreements.

Second, certain policy changes and pending bills are being discussed in legislative circles as possibly being ripe for amendments to the UFA process, including:

• Clarifying FDA’s role (or lack thereof) in the regulation of laboratory-developed tests, also known as LDTs (towards this end, a discussion draft of a bill called the Diagnostic Accuracy and Innovation Act was released on March 20th).
• Federal “Right to Try” legislation that would prohibit FDA from blocking a patient’s ability to access an experimental, unapproved treatment.
• The RACE for Children Act, which would update existing law on pediatric research to support the development of cancer treatments for children.
• The Lower Drug Costs Through Competition Act, which we mentioned in our first UFA blog post and would award priority review vouchers to sponsors after approval of certain types of generic drug products.
• Reforms to restricted distribution requirements for high-risk drugs and the Agency’s REMS authorities.
• Changes to the Orphan Drug Act to address perceived “abuse” of the system (although this potential legislative priority could be delayed in light of the recently initiated investigation by the General Accountability Office).
• And in contrast to the prior item, the Orphan Product Extensions Now Accelerating Cures and Treatments Act (OPEN ACT), which would grant a new exclusivity period to an approved drug that was repurposed for treatment of a rare, or orphan, disease.

One interesting concept that has come out of the March congressional hearings is whether FDA needs to be “penalized” in some way when it does not meet a commitment made in a user fee agreement with industry.  But time is short for any sort of re-negotiation of the agreements – even if the Trump Administration’s budgetary priorities are different from those of the Obama Administration, and the White House may welcome a re-opening of the agreements.  (Trump’s first budget blueprint, released on March 16th, proposes doubling FDA’s reliance on user fees.)  As we’ve noted before, without UFA reauthorizations, the Agency won’t be able to collect fees from industry after September 30, 2017.

Congress will leave for summer break after July 27, so that appears to be the operative drop-dead date by which all the UFAs need to be signed into law.  Delaying the reauthorizations past that point not only puts in jeopardy FDA’s activities with respect to application reviews and interactions with sponsors, but would also require the Agency to begin layoffs of employees who are funded by user fee revenues.  This could have long-term productivity impacts on the Agency even if reauthorization is completed after Congress’s August recess, since scientists who leave FDA could take jobs in the private sector, and the Federal government’s hiring process is not quick even when qualified candidates are available.

In the alphabet soup that is health and FDA law and policy (if you don’t know what we mean, are you sure you should be reading this blog?), one acronym that doesn’t get a lot of respect is “UFA.” This is the first is a series of blog posts that aim to educate and inform our readers about why the UFA acronym matters and how the UFA legislative process may be particularly significant in 2017.

UFA stands for “User Fee Act,” of which there are many flavors in this modern era – from the old-timer Prescription Drug User Fee Act (PDUFA), born in 1992, to the more toddler-ish Biosimilar User Fee Act (BsUFA) that joined us in 2012. Other important UFAs for the U.S. health care system and stakeholders are the Medical Device User Fee Amendments (MDUFA), which were enacted first in 2002, and the Generic Drug User Fee Amendments (GDUFA) that launched at the same time as their biosimilar companion.

These laws authorize FDA to collect so-called user fees from members of regulated industries, whether in the form of application review fees, facility registration fees, or other more unique fees like the annual Biosimilar Product Development, or BPD, fee. What’s critical to know about these UFAs is that they authorize FDA to collect user fees for only 5 years at a time – meaning that they reappear in Congress as “must pass” legislation every 5 years. If the various UFAs are not reauthorized, FDA can no longer require private entities to pay those large fees to the government and program/review activities will be adversely affected. The four current user fee authorizations we’ll be discussing all expire at the end of FY 2017 – September 30, 2017.

FDA and relevant industry stakeholders negotiate the details of these individual user fee programs – including how quickly an original new drug application or a medical device application must be reviewed, or the level of feedback the Agency must provide in response to certain industry submissions – and then those final UFA agreements are submitted to Congress and incorporated into the relevant UFA legislation. However, FDA’s user fee authorization bills have historically been vehicles for enacting other types of drug- and device-related provisions. For example, PDUFA IV, passed in 2007, included new authorities for FDA to require a Risk Evaluation and Mitigation Strategy for certain drug and biological products.

In an incredible timing coincidence, the 115^th Congress and the first year of the Trump Administration will also be the year in which FDA needs to secure reauthorization for its largest user fee programs. Given the “regulatory reform” themes emerging from both of those camps, even as Democrats and patient advocacy groups begin lining up to protect FDA and its public health mission, we expect the UFA process this year to be as contentious as it may be momentous after the dust has settled. The legislative activity will also be interesting to watch, as the Obama Administration’s FDA negotiated all of the user fee agreements with industry in 2016, but the Trump Administration is responsible for sheparding them through Congress. (The pick for FDA commissioner, Dr. Scott Gottlieb, was announced on March 10th and his confirmation timetable remains unknown.)

So as it develops over the next weeks and months, we will provide you with updates on on the UFAs’ progress through the legislative process and our predictions for what related (or unrelated) bills will be tacked on to them.  Indeed, the first UFA-related hearing took place on March 2, 2017 in front of the House Energy & Commerce Committee’s Subcommittee on Health.  That hearing focused on the new GDUFA and BsUFA programs that have been created since GDUFA I/BsUFA I were passed in 2012. It also considered a bill that has been introduced in the House to, in part, create a generic drug priority review voucher (which may also be the first possible amendment to GDUFA II).

So loosen those belts and be prepared for an abundance of alphabet soup!

The inauguration of President Donald Trump marks a significant transition for the executive branch and its various administrative agencies. As new leadership takes the helm at the Food and Drug Administration, healthcare stakeholders are bracing for potentially transformative changes. The broader transition to a Republican-led executive and legislative branch will undoubtedly impact how medical product developers navigate federal oversight.

Furthermore, the agency is actively tasked with implementing the extensive provisions of the recently enacted 21st Century Cures Act. The administration must also negotiate the critical reauthorization of several major User Fee Acts before the end of the fiscal year. These legislative mandates guarantee that federal regulators will remain exceptionally busy, even as their overarching enforcement philosophies begin to shift.

Reevaluating the Regulatory Pipeline

The incoming administration has publicly expressed a strong general aversion to expansive government regulation. Consequently, industry observers expect new agency leadership to thoroughly review and potentially discard several rules currently pending in the regulatory pipeline. Proposals listed in recent unified agendas may be permanently removed from consideration as the administration seeks to reduce bureaucratic burdens.

It also remains unclear how Congress will utilize the Congressional Review Act to address recent final rules. Lawmakers possess the authority to roll back specific regulations promulgated during the final months of the previous administration. Regardless of congressional action, stakeholders should not hold their breath waiting for pending proposed regulations to be finalized anytime soon.

The Future of Agency Guidance

Beyond formal regulations, the new administration can easily alter the agency’s informal policy landscape by modifying or withdrawing guidance documents. Unlike binding regulations, guidance documents are not subject to the lengthy notice-and-comment requirements of administrative law. A new FDA Commissioner can simply withdraw controversial or unpopular guidance drafts by publishing a brief notice in the Federal Register.

For instance, the heavily criticized draft guidance regarding quality metrics reporting for pharmaceutical manufacturers could be quickly rescinded. Conversely, the new administration might rapidly issue new guidance on topics where previous leadership hesitated, such as off-label communications. Many legal experts anticipate significant policy shifts designed to grant manufacturers greater flexibility in how they discuss unapproved product uses.

Shifting Enforcement Priorities

While the agency will undoubtedly maintain its strict policing of serious public health threats, priorities regarding lesser infractions may change. The new administration might adopt a more relaxed approach toward enforcing regulatory violations that do not directly endanger patient safety. For example, the recent surge in aggressive enforcement actions against cosmetic companies making structural claims about their products will likely subside.

Areas of Continued Stability

Despite the anticipated changes, certain complex regulatory frameworks are unlikely to experience major disruptions. The agency’s ongoing efforts to implement the Biologics Price Competition and Innovation Act and approve new biosimilars will almost certainly continue uninterrupted. Similarly, unraveling the intricate supply chain regulations established under the Food Safety Modernization Act would be administratively arduous and politically unpopular.

The administration’s stance on foreign pharmaceutical manufacturing, however, presents a unique variable. The President’s explicit criticism of outsourcing could potentially influence how the agency conducts international facility inspections in countries like China and India. Reducing these foreign inspections could inadvertently hinder manufacturers seeking the necessary regulatory clearance to export their medical products into the United States market.